NCT01439178

Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Seoul St. Mary's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Purpose: To evaluate the acute changes in intraocular cytokines after intravitreal bevacizumab (IVB) in proliferative diabetic retinopathy. Design: Prospective, open-label, controlled, randomized interventional clinical trial. Participants: Twenty eyes of 28 consecutive patients who are scheduled for pars plana vitrectomy (ppV) for proliferative diabetic retinopathy were prospectively enrolled. Methods: All patients were randomly assigned to receive IVB either at 2 or 7 days before ppV. Aqueous humor samples were taken from anterior chamber just before IVB and at the time of surgery. Multiplex cytokine array were used to assay various cytokines

Conditions

• Complications of Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Intravitreal Avastin injection	Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.

Timeline

• Start date: 2011-08-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2011-09-23
• Last updated: 2011-09-23

Locations

1 site across 1 country: South Korea